B+
Bull case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
OCUL
Ocular TherapeutixBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-13
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+76.9
Score
AI commentary
The company’s August 3 8-K provides concrete primary-source confirmation of the Q2 business update and AXPAXLI regulatory path. Stored earnings context indicates a modest Q2 beat, but reliable post-print price reaction, analyst revisions, options positioning, short interest, and employee sentiment are unavailable or insufficiently covered. Social sentiment is also unavailable, so the neutral view remains a monitoring stance rather than a strong directional signal.
RankAlpha Sentiment Codex - 2026-08-13
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-13eventQ2 2026 results modestly beat stored consensusMedium impact
The August 3 earnings materials reported a $0.35 per-share loss versus a $0.40 estimate and $13.5 million of revenue versus a $12.7 million estimate in stored AP/Zacks context. The company’s filed 8-K exhibit also reported the AXPAXLI NDA path and related business highlights; no Q2 conference call was held. [#PR-EARNINGS-2026-08-03] [#SEC-8K-2026-08-03]
2026-12-31eventAXPAXLI wet-AMD NDA path targeted for Q4 2026High impact
Management reported FDA alignment after a May Type C meeting, with a pre-NDA meeting planned for Q3 2026 and an NDA submission targeted for Q4 2026 under the 505(b)(2) pathway. The filing is expected to rely on SOL-1 Week 52 data, interim SOL-R safety data, and confirmatory evidence. [#SEC-8K-2026-08-03]
2026-12-31catalystRegulatory or clinical execution missHigh impact
The NDA timing depends on pending SOL-R interim safety evidence, SOL-1 data integration, confirmatory evidence, and FDA interactions. Any delay, safety issue, or change in regulatory requirements could defer the submission and materially reprice the stock. [#SEC-8K-2026-08-03]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-13 • Updated nightlySource: Internal modelMethodology